



PMI RESEARCH & DEVELOPMENT

# Genomics and Bioinformatics of Lung Diseases

*Dr. Nikolai V. Ivanov*

*Manager, Genomics Research & Technology*


*on behalf of*

*Biological Systems Research Department*


*April 25-27th, 2013*

# Background

- Lung Cancer, CVD and COPD
- Chronic obstructive pulmonary disease (COPD) is the 5<sup>th</sup> leading cause of death worldwide and cigarette smoking is the main cause of COPD
- Main features of COPD
  - Lung Inflammation, Chronic Bronchitis and Bronchiolitis
  - Lung Emphysema



[afarewellrescue.com](http://afarewellrescue.com)



1: Healthy Alveoli

2: Emphysematous Alveoli


[www.lung.ca/.../emphysema-emphyseme/index\\_e.php](http://www.lung.ca/.../emphysema-emphyseme/index_e.php)



PMI RESEARCH & DEVELOPMENT

# Background

- Human (Kohansal et al 2009) and animal experimental data (Milot J et al 2007; Wright JL et al 1994, 2006) suggest that lung can repair smoke-induced damage for some period before it eventually loses this ability to repair




# Objectives

---


- The objectives of COPD studies are
  - To establish C57BL/6 as a mouse model of cigarette smoke-induced COPD
  - To explore the impact of exposure to 3R4F on the onset and the development of COPD in C57BL/6 mice
  - To explore the impact of smoking cessation on the recovery of COPD in C57BL/6 mice
  - To determine the time point that animals start to develop irreversible emphysema
  - To assess the impact of smoking exposure and smoking cessation on the development of COPD based on whole genome gene expression profile.
  - Understand the underlying molecular mechanisms perturbed by smoke and smoking cessation



# Study Design - Exposure Groups and Duration



# Study Design – Experimental Set up




- Strain: Female C57Bl/6 mice
- Mainstream smoke from the Kentucky reference cigarette 3R4F; exposure: 750 µg total particulate matter (TPM)/L, 4 hours/day, 5 days/week
- Total duration of the study: 7 months



# Lung Inflammation - BALF


## Bronchoalveolar Lavage Fluid (BALF) Cells

### Total Free Lung Cells



# Emphysema: Lung Function

## Pressure-Volume Loop – Inhalation Curve




- Fresh Air Group
- Smoke Exposed Group
- Cessation 1 (Smoke 2m + Cessation 5m)
- Cessation 2 (Smoke 3m + Cessation 4m)
- Cessation 3 (Smoke 4m + Cessation 3m)

7 Months Exposure




# Emphysema: Histopathology/Morphometry


## Lung Morphometry after 7 Months of Exposure



Fresh Air Group



Smoke Exposed Group




Cessation Group  
(Smoke 2m + Cessation 5m)




# Network Biology for Systems Toxicology and Biomarker Discovery


## Respiratory Disease-associated Networks




## Biomarker



## Cardiovascular Disease-associated Networks



# New Paradigm in Toxicity Testing in the 21st Century



2007 – National Academy of Sciences, issued a landmark report "Toxicity Testing in the 21st Century: A Vision and Strategy"

**Vision:** Move away from evaluating apical health endpoints in animals - turn toward identification of toxicity pathways in *in-vitro* test systems

## Transformative change in toxicity testing

- to achieve testing of broad coverage of chemicals, mixtures, outcomes and life stages
- to significantly increase human relevance
- to reduce the cost and time required to conduct chemical safety assessments
- to reduce and potentially eliminate high-dose animal testing







Adapted from: *Toxicity Testing in the Twenty-first Century: A Vision and a Strategy*. The Board on Environmental Studies and Toxicology <http://nationalacademies.org/best>.



PMI RESEARCH & DEVELOPMENT



# Quantitative Mechanism-Based Systems Impact Assessment



MEASURE MULTIPLE PERTURBATIONS ACROSS MULTIPLE EXPERIMENTAL SYSTEMS

COMPUTE DIFFERENTIAL RESPONSE PROFILES FROM LARGE NUMBER OF MEASURED BIOLOGICAL VARIABLES

IDENTIFICATION OF BIOLOGICAL MECHANISMS PERTURBED BY A PRODUCT

QUANTIFICATION OF PERTURBATIONS OF INDIVIDUAL NETWORKS

QUANTIFICATION OF OVERALL PERTURBATION INDUCED BY PRODUCTS

Hoeng J, Deehan R, Pratt D, Martin F, Sewer A, Thomson TM, Drubin DA, Waters CA, de Graaf D, and Peitsch MC.



A network-based approach to quantifying the impact of biologically active substances. *Drug Discov Today* 17: 413-418, 2012.




PMI RESEARCH & DEVELOPMENT

# Quantitative Mechanism-Based Systems Impact Assessment

Experimental  
Data  
Production



BIOLOGICAL NETWORK RESPONSE





Systematic experiments across  
numerous test systems




PMI RESEARCH & DEVELOPMENT


# Quantitative Mechanism-Based Systems Impact Assessment




MEASURE MULTIPLE PERTURBATIONS ACROSS MULTIPLE EXPERIMENTAL SYSTEMS




COMPUTE DIFFERENTIAL RESPONSE PROFILES FROM LARGE NUMBER OF MEASURED BIOLOGICAL VARIABLES



IDENTIFICATION OF BIOLOGICAL MECHANISMS PERTURBED BY A PRODUCT



QUANTIFICATION OF PERTURBATIONS OF INDIVIDUAL NETWORKS



QUANTIFICATION OF OVERALL PERTURBATION INDUCED BY PRODUCTS


Hoeng J, Deehan R, Pratt D, Martin F, Sewer A, Thomson TM, Drubin DA, Waters CA, de Graaf D, and Peitsch MC.

A network-based approach to quantifying the impact of biologically active substances. *Drug Discov Today* 17: 413-418, 2012.



PMI RESEARCH & DEVELOPMENT

# Construction of BEL Encoded Network Models




Information 11 of 12 x

Source Term: kaof(ATM)  
Relationship Type: ^  
Target Term: TP53(P@S15)  
Evidence Text: ATM had intrinsic protein kinase activity and phosphorylated p53 on serine-15 in a manganese-dependent manner.  
species: Homo sapiens


Source Document  
Title: Activation of the ATM kinase by ionizing radiation and phosphorylation of p53.  
PubMedID: [9733515](#)  
Publication Date: 1998-09-11  
Citation: Science 1998 Sep 11 281(5383) 1677-9




# How Do We Use Transcriptomic Data?



Identification of potential downstream consequences of the data observations



Identification of upstream entities that are potential causes of the observed differential elements



Martin F, Thomson TM, Sewer A, Drubin DA, Mathis C, Weisensee D, Pratt D, Hoeng J, and Peitsch MC.

Assessment of network perturbation amplitude by applying high-throughput data to causal biological networks. *BMC Syst Biol* 6: 54, 2012




PMI RESEARCH & DEVELOPMENT


# Knowledgebase Model Properties




**Computable**



**Capture wide range of biology**




**Hierarchical structure**



**Updatable**

# Quantitative Mechanism-Based Systems Impact Assessment

## *Build and Maintain Biological Networks*



# Relevant Biological Network Models

## Cell Proliferation

## Inflammation

446 nodes  
727 edges  
8537 unique scorable measurements


206 nodes  
403 edges  
3637 unique scorable measurements

- Cell Proliferation
  - Represents growth factor signaling pathways and cell cycle regulation
  - Data includes measured phenotype
- Inflammation
  - Represents cytokine signaling to NFkB and AP-1 activation
  - No quantified phenotype associated with data







# Quantitative Mechanism-Based Systems Impact Assessment



- Compute Amplitudes of Perturbation for all identified Biological Networks
- Compare the Network Perturbation Amplitudes across responses between different perturbations
- Identify potential biomarkers indicative of overall Network Perturbation State



low med high

**QUANTIFICATION OF PERTURBATIONS OF INDIVIDUAL NETWORKS**


Martin F, Thomson TM, Sewer A, Drubin DA, Mathis C, Weisensee D, Pratt D, Hoeng J, and Peitsch MC.

Assessment of network perturbation amplitude by applying high-throughput data to causal biological networks. *BMC Syst Biol* 6: 54, 2012




PMI RESEARCH & DEVELOPMENT


# How Do We Use Transcriptomic Data?



Identification of potential downstream consequences of the data observations



Identification of upstream entities that are potential causes of the observed differential elements




Martin F, Thomson TM, Sewer A, Drubin DA, Mathis C, Weisensee D, Pratt D, Hoeng J, and Peitsch MC.

Assessment of network perturbation amplitude by applying high-throughput data to causal biological networks. *BMC Syst Biol* 6: 54, 2012



PMI RESEARCH & DEVELOPMENT

# NPA for Biological Impact Assessment and Mechanistic Interpretation



Related publications:



- *Assessment of Network Perturbation Amplitude by Applying High-Throughput Data to Causal Biological Networks*, Martin et al., *BMC Syst Biol.* 2012 May 31;6:54.
- *Quantification of biological network perturbations: Impact assessment and diagnostic using causal biological networks*, Martin et al., *In preparation.*
- *A network-based approach to quantifying the impact of biologically active substances*, Hoeng et al., *Drug Discov Today.* 2012 May;17(9-10):413-8.



# Quantitative Mechanism-Based Systems Impact Assessment




Product Biological Impact Factor is a numerical indicator of the impact of a product (a set of substances) on the system



|     |                  | System 1 |        |        |      | System 2 |        |        |      |
|-----|------------------|----------|--------|--------|------|----------|--------|--------|------|
| Exp | BN               | Prod 1   | Prod 2 | Prod 3 | Ctrl | Prod 1   | Prod 2 | Prod 3 | Ctrl |
|     | Apoptosis        | 10       | 3      | 2      | 0    | 5        | 4      | 3      | 1    |
|     | Oxidative Stress | 5        | 4      | 4      | 1    | 4        | 2      | 2      | 0    |
|     | Proliferation    |          |        |        |      |          |        |        |      |
|     | .....            |          |        |        |      |          |        |        |      |
|     | .....            |          |        |        |      |          |        |        |      |



# Summary of the Computational Process



**Perturbation Systems Biology Data**

**NPA Scores**

**Biological Impact Factor (BIF)**


**Biological Network Model**

**Score Aggregation**



PMI RESEARCH & DEVELOPMENT

# Study Design - Exposure Groups and Duration



# Differential Gene Expression Regulation in Lung


➔ Exposure to 3R4F

➔ Cessation

■ Up regulated genes

■ Down regulated genes

OMICS II  
FDR ≤ 0.05  
FC ≤ 1.3



Cessation of smoke exposure

1

2

3


4

5


7

Time (months)


# Biological Impact Factors (BIF's)




# Evolution of NPA in 3R4F and Cessation Exposure Type Regimens over Time - Cell Oxidative Stress Network




Quantification of the perturbation of 70 cause-and-effect mechanistic networks



# Evolution of NPA in 3R4F and Cessation Exposure Type Regimens over Time - IPN/Macrophage activation Network




Quantification of the perturbation of 70 cause-and-effect mechanistic networks




PMI RESEARCH & DEVELOPMENT

# Consistent Trends between Network Models (primary tissue) & BALF (surrogate measurements)

## Lung NPA Score



## BALF Measurements





Julia Hoeng, Marja Talikka, Florian Martin; Alain Sewer, Xiang Yang, Anita Iskandar, Walter Schlage, Manuel C. Peitsch  
**Case Study: The Role of Mechanistic Network Models in Systems Toxicology (manuscript submitted).**





# NPA Scores Indicate Residual Signaling in Primary Tissue (Lung)

## Lung NPA Score




## BALF Measurements



# New Technologies


**A**

## Microarray



Based on a priori knowledge  
Short run time (days)  
Low data throughput (Mb)

## High-throughput sequencing



No need for prior knowledge  
Long run time (weeks)  
High data throughput (Gb)




# The Affymetrix Gene Expression and Illumina Sequencing Platforms

|                               | <b>Affymetrix Chip</b>                                 | <b>Illumina RNA-seq</b>  |
|-------------------------------|--|--|
| <b>Technology</b>             | Gene-centric<br>(limited to genes present on the chip) | Sequence-centric<br>(genes, transcript isoforms,...)               |
| <b>Measured datapoints</b>    | ~30'000  | Unlimited  |
| <b>Time to generate data</b>  | ~3 days  | ~14 days   |
| <b>Samples per run</b>        | 96   | Typical: 4 samples*16 lanes = 64<br>Max: 12 samples*16 lanes = 192 |
| <b>Analysis methods</b>       | Standardized<br>Well-established                       | In development   |
| <b>Data storage footprint</b> | Low (Mb)   | High (Gb)  |





# Future Developments ...

DNA





- Genomics
- Epigenomics

RNA





- Transcriptomics
- miRNA

Protein



- Proteomics
- Phosphoproteomics

Metabolites



- Metabolomics
- Lipidomics



# Summary

---

- Obvious lung emphysema was observed by histopathological/morphometric analysis after 2 months of mainstream cigarette smoke exposure.
- Mainstream cigarette smoke exposure cessation reverses the effects of inflammation, lung function changes and histopathological/morphometric changes.
- A strong inflammation component was observed from the gene expression profile followed by senescence and DNA damage. The molecular changes are supported by the biological endpoints.
- PMI computational method based on mechanistic networks enables us to identify the key biological processes involved.
- New technologies (e.g. Next Generation Sequencing and Mass Spectroscopy Proteomics) would allow us to evaluate the effects of cigarette smoke exposure and cessation at the DNA and protein levels.



# Acknowledgement

## Selventa-USA

Jurjen W. Westra  
Michael J. Maria  
David de Graaf  
Renée Deehan  
Dexter Pratt  
Ty M. Thomson,  
David A. Drubin  
Andrea L. Mathews

## PMIRL-Singapore

Magali Russell  
Shen Yi  
Jan Verbeeck  
Blaine Phillips  
Didier Goedertier  
Clement Foong  
Teo Hutt Wang  
Woon Ching Qing  
Eric Yew  
Chor Kiat Yeo

## PMI R&D Switzerland

Manuel C. Peitsch  
Julia Hoeng  
Marja Talikka  
Patrick Vanscheeuwijck  
Nveed Chaudhary  
Emilija Veljkovic  
Michael Peck  
Florian Martin  
Yang Xiang  
Grégory Vuillaume  
Stefan Lebrun  
Carine Poussin  
Carole Mathis  
Sandra Wagner  
Ulrike Kogel  
Walter Schlage  
Vincenzo Belcastro  
Alain Sewer  
Sam Ansari



---

# Thank You



PMI RESEARCH & DEVELOPMENT